Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.80 -0.69% 115.00 1,029,121 16:35:09
Bid Price Offer Price High Price Low Price Open Price
114.20 115.00 119.20 114.20 116.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.53 -30.35 -22.80 207
Last Trade Time Trade Type Trade Size Trade Price Currency
18:54:16 O 1,601 115.00 GBX

4d Pharma (DDDD) Latest News

More 4d Pharma News
4d Pharma Investors    4d Pharma Takeover Rumours

4d Pharma (DDDD) Discussions and Chat

4d Pharma Forums and Chat

Date Time Title Posts
22/4/202119:064D Pharma 2018 - from Ј2 back up to Ј10+21,158
18/2/202120:044d Pharma586
17/11/202020:53DDDD : 4D and the Microbiome sector-
09/11/202007:424D Pharma - Best Risk Reward Play on AIM12
08/3/202021:164D Pharma (DDDD) One to Watch 8

Add a New Thread

4d Pharma (DDDD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
18:09:07115.00652749.80O
18:08:49115.001,6011,841.15O
17:54:21115.001,6011,841.15O
17:54:21115.00652749.80O
16:37:06115.001,6011,841.15O
View all 4d Pharma trades in real-time

4d Pharma (DDDD) Top Chat Posts

DateSubject
22/4/2021
09:20
4d Pharma Daily Update: 4d Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DDDD. The last closing price for 4d Pharma was 115.80p.
4d Pharma Plc has a 4 week average price of 102p and a 12 week average price of 102p.
The 1 year high share price is 183p while the 1 year low share price is currently 35.60p.
There are currently 180,299,728 shares in issue and the average daily traded volume is 2,548,691 shares. The market capitalisation of 4d Pharma Plc is £207,344,687.20.
16/4/2021
09:51
ambyth: As per 4D Pharma’s rns and tweet; CEO Duncan Peyton and CSO Alex Stevenson will participate in a fireside chat with analyst Chris Howerton at the Jefferies Microbiome-Based Therapeutics Summit. Https://twitter.com/4dpharmaplc/status/1382578181677326339 It is, in my view, important to note that Chris Howerton is the SAME Investment Bank analyst at Jefferies who last week increased (US) EVLO Evelo Bisociences share price Target by 63% from $11 to $18 and recommendation from Neutral to Buy ahead of numerous catalysts. EVLO shares rose 18% that day. Https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Jefferies+Upgrades+Evelo+Biosciences+Inc+%28EVLO%29+to+Buy+Ahead+of+Numerous+Catalysts/18246396.html The “Fireside chat”/Presentation takes place next Thursday, April 22, 2021 at 1:00 p.m. BST (8:00 a.m. ET). 4D have now put up a link for the Webcast which we can register for to watch live at Https://wsw.com/webcast/jeff173/dddd.l/2027740 As per 4D Pharma’s rns, an archived replay of the webcast will subsequently be available for 90 days. 
16/4/2021
07:55
pistolwhip: 4d Pharma PLC Directors' Subscription for new Ordinary Shares 16/04/2021 7:00am UK Regulatory (RNS & others) 4d Pharma (LSE:DDDD) Intraday Stock Chart Friday 16 April 2021 Click Here for more 4d Pharma Charts. TIDMDDDD RNS Number : 6612V 4d Pharma PLC 16 April 2021 4D pharma plc Directors' Subscription for new Ordinary Shares Leeds, UK - 16 April 2021 - 4D pharma plc (AIM: DDDD; Nasdaq: LBPS) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announces that further to the announcement released on 22 March 2021 which detailed the Company's private placement to raise approximately $25.03 million (GBP18.01 million) (the "Fundraising"), Duncan Peyton (Chief Executive Officer) and Alex Stevenson (Chief Scientific Officer) have agreed to subscribe for, in aggregate, approximately $2.0 million (GBP1.44 million) of new ordinary shares of GBP0.0025 each (the "Subscription Shares") at GBP1.10 ($1.52) per share (the "Subscription Price"). Admission and dealings Application has been made to the London Stock Exchange plc for admission of the Subscription Shares to trading on AIM ("Admission") and Admission is expected occur at 8.00 a.m. on 22 April 2021. The Subscription Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of the Company, including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after the date of issue of the new ordinary shares. Related party transaction The details of the Subscription Shares are set out below: Director Existing Ordinary Ordinary Percentage Shares Subscription Consideration Shares of Enlarged currently Shares subscribed per Subscription held Share Capital held for Share on Admission on Admission Duncan Peyton 8,855,931(1) 658,840 GBP1.10 9,514,771 5.28% Alex Stevenson 8,699,624(2) 658,840 GBP1.10 9,358,464 5.19% (1) In the circular dated 26 February 2021 this was disclosed as 8,855,059 (2) In the circular dated 26 February 2021 this was disclosed as 8,698,961 The Directors' participation in the Fundraising, as set out above, constitutes a related party transaction pursuant to Rule 13 of the AIM Rules for Companies. The Independent Directors, being the Directors not participating in the Subscription, having consulted with N+1 Singer, the Company's nominated adviser, consider that the individual, respective subscriptions by Duncan Peyton and Alex Stevenson in the Fundraising are fair and reasonable insofar as shareholders are concerned. Total Voting Rights Following Admission, 4D's enlarged issued share capital will comprise 180,299,728 ordinary shares. The total number of voting rights in the Company will be 180,299,728. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority. Contact Information: 4D pharma Investor Relations: ir@4dpharmaplc.com N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000 Philip Davies / Iqra Amin / James Fischer (Corporate Finance) Tom Salvesen (Corporate Broking) Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500 Dominic Wilson / Phil Walker Stern Investor Relations, Inc. +1-212-362-1200 Julie Seidel Julie.seidel@sternir.com Image Box Communications +44 (0)20 8943 4685 Neil Hunter / Michelle Boxall neil@ibcomms.agency / michelle@ibcomms.agency Forward-Looking Statements This announcement contains "forward-looking statements." All statements other than statements of historical fact contained in this announcement, including without limitation statements regarding the admission and trading of Ordinary Shares, are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. All of the Company's forward-looking statements involve known and unknown risks and uncertainties, some of which are significant or beyond its control, and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. The foregoing factors and the other risks and uncertainties that could cause actual results to differ materially include potential delays in the process of Admission. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of its forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law. 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Duncan Peyton -------------------------- ------------------------------------------------- 2 Reason for the notification ----------------------------------------------------------------------------- a) Position/status Chief Executive Officer -------------------------- ------------------------------------------------- b) Initial notification Initial /Amendment -------------------------- ------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------- a) Name 4D Pharma plc -------------------------- ------------------------------------------------- b) LEI 213800O49VYSXWE2ZD52 -------------------------- ------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------------- a) Description of the Ordinary shares of 0.25 pence each financial instrument, type of instrument GB00BJL5BR07 (Ordinary Shares) Identification code -------------------------- ------------------------------------------------- b) Nature of the transaction Purchase of Ordinary Shares pursuant to the Fundraising -------------------------- ------------------------------------------------- c) Price(s) and volume(s) Price Volume -------------------------- ----------------------- ------------------------ 110 pence per Ordinary 658,840 Ordinary Shares Share -------------------------- ----------------------- ------------------------ d) Aggregated information N/A - Aggregated volume - Price -------------------------- ------------------------------------------------- e) Date of the transaction 15 April 2021 -------------------------- ------------------------------------------------- f) Place of the transaction Off market transaction -------------------------- ------------------------------------------------- 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Alex Stevenson -------------------------- ------------------------------------------------- 2 Reason for the notification ----------------------------------------------------------------------------- a) Position/status Chief Scientific Officer -------------------------- ------------------------------------------------- b) Initial notification Initial /Amendment -------------------------- ------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------- a) Name 4D Pharma plc -------------------------- ------------------------------------------------- b) LEI 213800O49VYSXWE2ZD52 -------------------------- ------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------------- a) Description of the Ordinary shares of 0.25 pence each financial instrument, type of instrument GB00BJL5BR07 (Ordinary Shares) Identification code -------------------------- ------------------------------------------------- b) Nature of the transaction Purchase of Ordinary Shares pursuant to the Fundraising -------------------------- ------------------------------------------------- c) Price(s) and volume(s) Price Volume -------------------------- ----------------------- ------------------------ 110 pence per Ordinary 658,840 Ordinary Shares Share -------------------------- ----------------------- ------------------------ d) Aggregated information N/A - Aggregated volume - Price -------------------------- ------------------------------------------------- e) Date of the transaction 15 April 2021 -------------------------- ------------------------------------------------- f) Place of the transaction Off market transaction -------------------------- -------------------------------------------------
12/4/2021
22:04
ambyth: Evelo Biosciences share price up 18% in US today after Jefferies Investment Bank analyst increased share price Target by 63% from $11 to $18 and recommendation from Neutral to Buy ahead of numerous catalysts. Https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Jefferies+Upgrades+Evelo+Biosciences+Inc+%28EVLO%29+to+Buy+Ahead+of+Numerous+Catalysts/18246396.html Sector starting to stir?
12/4/2021
15:29
pistolwhip: Q: Was the strong rise seen last year, up till October, driven solely by the expectation and hopes over the Blautix trial? I think not. Whilst the impending IBS readout surely stoked the fire, matching newsflow to price movement, I note the shares really took off only after the 40% benefit data flowing from Oncology, and it didn't show any signs of cooling off either. Those Oncology readouts are still perfectly valid and the potential all remains. Oncology has since expanded out into part B, with increased numbers and over multiple sites in the US and for differing tumour types. Any signals of efficacy over a larger patient set and the shares should go on an excellent run. According to DP the market can expect further data in June and September (as well as a big readout on Asthma). It's going to be interesting to see if the share price refinds that strength as we move closer to more clinical data. I think it will. In recent times, the overall trial/readout calendar combined with corporate developments since, have so far conspired to stall the same consistent rise seen in 2020. That could be about to change. Time to salvage the baby from the thrown bathwater. The market seems to be discounting far too much at present. With the company well-financed, with corporate developments now done, not to mention a decent run of upcoming clinical news, I can see the shares trending higher over the near to medium term. We also now have a whole new market to engage with too. ADYOR AIMO
07/4/2021
14:14
techtrend: Isn't price the answer to any liquidity issues on Nasdaq? In other words, if I can sell for 15% more as LBPS I might convert some AIM DDDD shares to sell stateside. If price remains the same in both markets, there is no incentive. If a price differential arises in the future we now know what to do to sell DDDD as LBPS and if enough people did it it would solve the liquidity issues - perhaps that is the idea behind the RNS?
07/4/2021
10:18
jackrussell3: We could stay on AIM with massive share float sitting idle along with our share price reducing prospects of any US pharma takeover due to exchange rate & dual listing regulatory issues. Or we could just delist from AIM, convert 8 into 1 share thereby reducing our share float & leave demand & supply of liquid Nasdaq market to drive up our share price
02/4/2021
09:02
daveweld2: Glasswala, the cynic would suggest they passed approval for 600k a year salary post merger and they needed price pegged around 110p rather than allowing price to grow naturally pre/post launch, they did this by surprisingly announcing fund raise prior to listing, this took the steam out of the whole event.... we all knew raise was coming but expected it at a higher price post listing...Duncan and Alex announce buy in of 600k each at 110p a coincidence maybe but certainly fitted their own script... has no bearing on long term share price nor science which remain solid however I believe we have been party to a carefully managed situation....They believe science is strong therefore share price will rebound long term, Heard pigs at a trough mentioned a few days ago.... rings true..
28/3/2021
14:31
royalalbert: All this talk about Duncan and his presentation style will be forgotten once the share price reacts to news. In fact if we doubled in six weeks, he would be gods gift. Peeps always try to find fault as share prices fall, let the science do the talking and we will arrive at our goals eventually. Of course if you are deramper you love this board at this present time as it suits your motive.
25/3/2021
15:10
kcowe: Should hold.... 110placing price.. no reason to fall lower , beyond any reason to keep short term investors motivated to hold shares . Share prices rise because a continued regular profitable interest. if everyone was a long termer there would be no market.No shares changing hands . short term money drives price so what short term interest news is to be had.?That will decide direction of price.
24/3/2021
11:28
jules winnfield: You should all know that the Stigologist / Stockonomist, who is proven to be at least 95% wrong on Share Price rise forecast is also attempting to avoid any accountability based on evidence by editing his posts retrospectively. Having been proven to be so wrong, between yesterday and today he has now edited his post 18178 of 20th Feb to remove the entire sentence which said “I had expected 200p prior to NASDAQ listing but I think given this current momentum can not rule out 300-400p (given Portage example up 100% in 5 trading days since confirming they'll uplist on Feb 25th. Current Portage Mkt Cap is $450m)” So it now simply says: “Weekly setting up perfectly for a big breakout”. Be warned. Stig will mislead you and then he will also attempt to edit the past to suit himself The Stigologist / Stockonomist is proven to be at least 95% wrong on Share Price rise forecast Ignore Stig, he will damage your wealth and it turns out he is a shameless coward too
4d Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
DDDD
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210422 18:33:42